News + Font Resize -

Immunovaccine licenses vaccine delivery technology to Pfizer Animal Health
Halifax, Nova Scotia | Wednesday, November 25, 2009, 08:00 Hrs  [IST]

Immunovaccine Inc, a vaccine development company, announced the signing of an exclusive, worldwide license agreement with Pfizer Animal Health for Immunovaccine's patented vaccine delivery technology. Pfizer Animal Health said it plans to develop enhanced cattle vaccines incorporating Immunovaccine's technology. Under the terms of the agreement, which were not disclosed, Immunovaccine will receive upfront signing fees in addition to subsequent milestone payments and royalties on any Immunovaccine-delivered vaccines developed by Pfizer Animal Health.

"Pfizer Animal Health is known around the world for its treatment and prevention of disease in cattle, and we are pleased to secure a further licensing agreement designed to advance their development of promising vaccines for veterinarians and producers," said Dr Randal Chase, president and CEO of Immunovaccine. "This is further validation of the commercial potential of our technology."

"We see global demand growing among beef and dairy producers for new vaccines that can be safely and easily administered," said Juan Ramon Alaix, president, Pfizer Animal Health. "Pfizer looks forward to developing cattle vaccines incorporating Immunovaccine technology that will contribute to meeting this demand," Alaix said. Pfizer Animal Health is currently also licensing other Immunovaccine technology for the development of particular livestock vaccines.

Compared to conventional vaccines, the strength of Immunovaccine's platform lies in its ability to reduce the number of required doses and to significantly enhance antibody onset and duration. The power and versatility of Immunovaccine's technology to combine with a variety of antigens and to induce both humoral and cellular immune responses make it the vaccine delivery system of choice for Immunovaccine's current and potential biotechnology partners.

Immunovaccine is a vaccine development company focused on commercialization of its novel vaccine candidates.

Post Your Comment

 

Enquiry Form